Clinical Trial Update: Two-way Interaction Between Alisporivir and EDP239 [Phase 1]

View source ↗

Summary

A Phase 1 study evaluated the pharmacokinetic and safety interaction between alisporivir and EDP239 in Hepatitis C and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Alisporivir (alisporivir)
• EDP-239 (EDP-239)

Snippet

Sponsor: Enanta Pharmaceuticals, Inc | Conditions: Hepatitis C Virus | Phase 1 | Status: COMPLETED